Endothelial dysfunction in arterial hypertension: focus on the combination of trandolapril and verapamil
Abstract
The beneficial effects of the combination of trandolapril and verapamil (combined medication Tarka) on endothelial function in arterial hypertension (AH) are presented. Antihypertensive effectiveness of the medication is discussed, in particular, among AH patients with renal disease, other target organ pathology, and diabetic nephropathy.
References
1. Van Zweiten PA Endothelial dysfunction in hypertension. A critical evaluation. Blood Press Suppl 1997; 2: 67-70.
2. Белоусов Ю.Б., Намсараев Ж.Н. Эндотелиальная дисфункция как причина атеросклеротического поражения артерий при артериальной гипертензии. Фарматека 2004; 6: 62-72.
3. Мишина Е.А., Симаков А.А., Зарубина Е.Г. Роль сосудистого эндотелия в развитии терапевтической патологии. Самара 2008; 218 с.
4. Bonner G, Preis S, Schunck U, et al. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertesive humans. J Cardiovasc Pharmacol 1990; 15 (Suppl 6): 46-56.
5. Scholkens BA, Unger T. ACE Inhibitors, Endotelial function and Atherosclerosis. Amsterdam Media Medica Publ. March 1993.
6. Webb D, Vallance P. Endothelial Function in Hypertension.1997. Springer-Verlag Berlin Heidelberg.
7. Luscher TF, Wenzel RR, Moreau P, Hiroyuki T. Vascular protective effects of ACE inhibitors and calcium antagonists: theoretical basis for a combination therapy in hypertension and other cardiovascular diseases. Cardvasc Drags and Therapy 1995; 9: 509-23.
8. Toyoshi H, Nasa Y, Kohsaka Y, et al. The effect of chronic with trandolapril on syslic AMP-and cyclic GMP-depend relaxation in aortic segments of rats with chronic heart failure. Brit J Pharmacol 1998; 123: 344-52.
9. Levick S, Fenning A, Brown L. Increasd calcium influx mediates increased cardiac stiffnes in hyperthyroid rats. Cell Biochem Biophys 2005; 43: 53-9.
10. Rubio-Guerra AF, Vargas-Robles H, Rodrigues-Ayala, G et al. The effect of tradolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin and Exper Hypertens 2008; 30: 682-8.
11. Ruilope LM, de la Sierra A, Moreno E, et al. Prospective comparison of therapeutical attitudes in hypertensive type 2 diabetic patients uncontrolled on monotherapy. A randomised trial: the EDICTA study. J Hypertens 1999; 17: 1917-23.
12. Nieto J, Gomez-Campdera F, Rodriguez-Perez JC, et al. Better control of hypertensive type 2 patients with albuminuria: a prospective randomized double-blind trial. J Am Soc Nephrology 1999; 10: 131A.
13. Bakris G, Molitch M, Hewkin A, et al. on behalf of the STAR Investigators. Differences in Glucose Tolerance Between Fixed-Dose Antihypertensive Drug Combinations in People With Metabolic Syndrome. Diabetes Care 2006; 29: 2592-7.
14. Bakris GL, Molitch M, Zhou Q, et al. Reversal of Diuretic-Associate Impaired Glucose Tolerance and New-Onset Diabets: Results of yhe STAR-LET Study. J Cardiometab Syndr 2008; 3: 18-25.
15. Barkis GL, Weir MR, DeGuattro V, McMahon FG. Effect of an ACE inhibitor calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney International 1998; 54: 1283-9.
16. Ruggeneti P, Remuzzi G on behalf of the BENEDICT studi group. Primary prevention of renal failure un diabetic patients. J Hypertens 1998; 16(Suppl 1): S95-7.
17. Вартанова О.А., Захарова В.Л. Комбинированная терапия артериальной гипертензии ингибитором АПФ трандолаприлом в виде монотерапии и в сочетании с верапамилом и гипотиазидом. В кн. Актуальные вопросы внутренней медицины и педагогики. Москва 1999; 181-7.
18. Маколкин В.И., Подзолков В.И., Ренскова Т.В. Ингибитор третьего поколения трандолаприл (гоптен) в лечении гипертонической болезни. Кардиология 2000; 5: 51-4.
19. Мартынов А.И., Аветян Н.Г., Гороховская Г.Н. и др. Антигипертензивные и органопротективные эффекты комбинированной терапии ингибитором ангиотензинпревращающего фермента и антагонистом кальция. Cons Med 2006; 11: 15-20.
20. Чихладзе Н.М., Чазова И.Е. Нефропротективная эффективность комбинированной терапии трандолаприлом и верапамилом у больных артериальной гипертонией. Cons Med 2003; 5: 652-5.
21. Сидоренко Б.А., Преображенский Д.В., Савченко М.В. и др. От верапамила и трандолаприла к их фиксированной комбинации — препарату “Тарка”. Фарматека 2002; 6: 3-17.
22. Ovbiagele B. Microalbuminuria: Risk factor and potential therapeutic target for stroke? J Neurolog Scien 2008; 271: 21-8.
23. Beamer NB, Coull BM, Clark WM, et al. Arch Neurol 1999; 56: 699-702.
24. Yuyun MF, Khaw K.-T, Luben R, et al. Day Microalbuminuria and stroke in a British population: the European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) population study. J Intern Med 2004; 255: 247-56.
25. Stowik A. Microalbuminuria in nondiabetic patients with acute ischemic stroke: revalence, clinical correlates, and prognostic significance. Cerebrovasc Dis 2002; 14: 15-21.
Review
For citations:
Makolkin V.I. Endothelial dysfunction in arterial hypertension: focus on the combination of trandolapril and verapamil. Cardiovascular Therapy and Prevention. 2010;9(4):95-100. (In Russ.)
Views:
431
Email this article 
